10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

EPN3 Antibody (N-term) Blocking Peptide

Synthetic peptide
Catalog # BP6527a

Specification

EPN3 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession Q9H201

EPN3 Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 55040

Other Names
Epsin-3, EPS-15-interacting protein 3, EPN3

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6527a was selected from the N-term region of human EPN3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

EPN3 Antibody (N-term) Blocking Peptide - Protein Information

Name EPN3

Cellular Location
Cytoplasm. Cytoplasm, perinuclear region Cytoplasmic vesicle, clathrin-coated vesicle. Nucleus Note=Concentrated in the perinuclear region and associated with clathrin-coated vesicles close to the cell periphery. May shuttle to the nucleus

Tissue Location
Detected in migrating keratinocytes from wounded skin, but not in differentiating keratinocytes or in normal skin Detected in chronic wounds, basal cell carcinoma and ulcerative colitis.

EPN3 Antibody (N-term) Blocking Peptide - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

EPN3 Antibody (N-term) Blocking Peptide - Images

EPN3 Antibody (N-term) Blocking Peptide - Background

EPN3 belongs to the epsin family.

EPN3 Antibody (N-term) Blocking Peptide - References

Spradling,K.D., J. Biol. Chem. 276 (31), 29257-29267 (2001)Spradling,K.D., J. Invest. Dermatol. 115 (2), 332 (2000)